Back to News
Jan 5, 2026 12:30 PM

Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost

Novo Nordisk A/S (NYSE:NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.

Novo Nordisk stock is charging ahead with explosive momentum. What’s fueling NVO momentum?

Wegovy pill showed an average weight loss of about 17% (16.6%) when used along with a reduced-calorie diet and exercise, and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.

When looking at the efficacy regardless of whether all patients stayed on treatment, an average weight loss of about 14% (13.6%) was achieved by people taking the Wegovy pill compared to about 2% (2.4%) for the placebo.

Also Read: Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat

Where Can You Buy?

Wegovy is available through a range of options, including U.S. pharmacies such as CVS (NYSE:CVS) and Costco (NASDAQ: